stock rocketed up more than 70 percent in midday trading Monday after a FDA panel voted in favor of the company's primary drug under development.
The majority of an FDA advisory committee voted "yes" when asked whether data supports the safety of Dyanvax's Heplisav.
"[The] panel vote is a major win for Dynavax," J.P. Morgan analyst Anupam Rama wrote in a note. "We now believe that Heplisav has a high...
More